Investor AB Splits Mölnlycke While the Tariff Refund Party Ends

Patricia's 26% EBITA jump leans on a refund management says is already mostly booked — the durable news is a two-company Mölnlycke and a competition problem nobody wants to name

INVE-B.ST · Earnings Call · 2026-10-16

The refund that flattered the quarter

Investor AB's Q3 headline reads like a compounding machine: Patricia Industries delivered 7% organic sales growth and adjusted EBITA up 26%, and the shares returned 1% while adjusted NAV rose 4% to SEK 1,258 billion. But peel the onion and the quarter's most-quoted number rests on three things that are not organic: M&A, positive FX, and tariff refunds. Jenny Ashman Haquinius put a number on the last one — “roughly a percentage point on the margin that comes from tariff refunds” — Jenny Ashman Haquinius, Chief Financial Officer · 2026-10-16 — and Christian Cederholm effectively called the top: “to the best of our knowledge, we have seen the majority of tariff refunds” — Christian Cederholm, Chief Executive Officer · 2026-10-16. What makes this interesting is that the company's single highest-momentum keyword this quarter is a windfall, not a strategy. And it is not a private one. Globally, Tariff Refund dominated the market's editorial keyword board in the prior period, and the phrasing net benefit from tariff refunds ran through dozens of unrelated industrials and consumer names. Investor is not ahead of a wave here; it is surfing the back of one that is already breaking on the beach. Johan Sjöberg of Nordea heard it too, extracting the concession that Q3 was the peak — “It was slightly less in Q2 as per my recollection.” — Jenny Ashman Haquinius, Chief Financial Officer · 2026-10-16 Notice also the sign flip. In January, tariff was a cost: “it's roughly 1 percentage point or so still impacting margins” — Jenny Haquinius, Chief Financial Officer (CFO) · 2026-01-22. By October 2025 it was “the actual cost is less than 1%” — Jenny Haquinius, CFO · 2025-10-16. Twelve months later the same percentage point arrives as a tailwind. That is a round trip, not a trend — and it matters for anyone annualising Q3 margins into 2027. Management was at least honest that the price increases taken to cover tariffs won't be handed back. Jenny: “It is a mix, but we do not foresee any major reversals as of now.” — Jenny Ashman Haquinius, Chief Financial Officer · 2026-10-16 So the pricing sticks and the refunds are one-off. The underlying Patricia business — underlying markets growing low-to-mid single digits in wound care, roughly 8% historically at Nova — is far duller than the reported 26%.

Mölnlycke becomes two

The genuinely new thing this quarter is the intended separation of Mölnlycke into two standalone companies: Mölnlycke, holding Wound Care and antiseptics, and Mölnlycke Surgical, holding ORS and gloves. "Separation" appears in Investor's keyword record as a fresh mover — it has no meaningful lineage in the prior twelve quarters of this company's vocabulary, unlike Wound Care, acute care and Optilume, which are perennial. The rationale is accountability, not valuation. Cederholm was unusually direct that this is not a sale process dressed up as a reorganisation:

The motivation for separating is not to sell one or both of the companies nor is it to enhance valuation by way of applying a different peer set.
Christian Cederholm, Chief Executive Officer · 2026-10-16

He was equally direct that nobody should expect this to look clever in a spreadsheet: “I wouldn't say it's been lacking, but I would say that our experience from separating businesses is that it's hard to capture in PowerPoint or Excel” — Christian Cederholm, Chief Executive Officer · 2026-10-16. Duplicated boards, duplicated back office, and, on his own admission, "separation typically means that you will have to duplicate certain costs." Asked when sum-of-the-parts turns positive, he offered nothing: "I wish I could give you a clear answer." That is the honest answer, and it is the tension in the story. Investor has a fifteen-quarter habit of presenting Patricia as a stable compounding platform; this is the first quarter where it is voluntarily introducing friction — cost duplication, organisational distraction and a leadership vacuum — into its largest asset, for a payoff measured in years.

The competition line nobody headlines

Buried at rank five in the company's own keyword set is tough competition — a phrase with no prior history in this name. Wound Care grew 6% organically and the U.S. grew "in line with the market," which in the prevention segment means ceding the price argument. Compare July, when Jenny described the landscape with far more comfort: “we are seeing the same kind of competitors as we typically see” — Jenny Ashman Haquinius, CFO · 2026-07-16. Three months later, on a webcast question about whether the split is a response to Chinese pressure, the answer was softer — "I wouldn't say that it's linked to Chinese competition specifically, but I think overall, a competitive global market." The related keyword Chinese competition is in the record but unranked; that placement is itself the message. On ORS the diagnosis is structural: Cederholm's one-line summary was “it's primarily a European business” — Christian Cederholm, Chief Executive Officer · 2026-10-16 — a slower-growth, budget-pressured geography, which is exactly why pairing it with gloves and cutting it loose from the faster Wound Care engine makes industrial sense.

What stopped being said

Three silences are worth flagging. First, AI. A year ago Investor was fielding questions on Sferical AI, Fortnox and AI-driven budget shifts; this quarter the topic barely surfaces, and when asked whether the fund should trim ABB — roughly 20% of NAV and an AI-adjacent winner — the answer was a flat no: “Selling on the margin is not really a tool in our toolbox as we see it.” — Christian Cederholm, Chief Executive Officer · 2026-10-16 Second, buybacks. The final audience question on returning more cash got a recitation of the three capital-allocation priorities and nothing else. Third, Permobil, which was a momentum keyword two years ago and now gets one line: “Permobil saw yet another quarter with muted growth.” — Jenny Ashman Haquinius, Chief Financial Officer · 2026-10-16 What did work was the balance sheet. Leverage of 1.8%, SEK 29 billion of cash, and a Moody's upgrade from Aa3 to Aa2 — a genuine vote of confidence that costs nothing to mention and therefore reads as real.

Verdict

Investor AB's quarter is a tale of two earnings qualities. The reported one — 26% Patricia EBITA — is a peak-cycle artefact assembled from refunds, FX and acquisitions, and management has now told you so. The durable one is a bet that splitting Mölnlycke into two sharper companies creates more value over a decade than the cost duplication destroys over two years. That bet is unprovable today, which is precisely why the stock's 1% quarterly return lagged a Listed Companies portfolio that itself lagged SIXRX by a point. Patient capital, thin catalyst.